Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy

Lancet Oncology

Volumn 8, Issue 1, 2007, Pages 63-74

  Zahra, Mark A ^a   Hollingsworth, Kieren G ^b   Sala, Evis ^c   Lomas, David J ^c   Tan, Li T ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

CANCER RADIOTHERAPY; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; INDIVIDUALIZATION; MICROENVIRONMENT; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; TISSUE PERFUSION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS;

EID: 33845645028     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)71012-9     Document Type: Review

References (74)

1. Bentzen S. Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 77 (2005) 227-230
2. Overgaard J., Hansen H., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362 (2003) 933-940
3. Dische S., Saunders M., Barrett A., et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44 (1997) 123-136
4. Saunders M., Dische S., Barrett A., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 52 (1999) 137-148
5. Overgaard J., Hansen H., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46 (1998) 135-146
6. Kaanders J., Bussink J., and van der Kogel A. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3 (2002) 728-737
7. Boss E., Massuger L., Pop L., et al. Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma. J Magn Reson Imaging 13 (2001) 600-606
8. Hoskin P., Saunders M., Goodchild K., et al. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 72 (1999) 1093-1098
9. Horsman M., and Overgaard J. The oxygen effect. In: Steel G. (Ed). Basic clinical radiobiology. 2nd edn. (1997), Arnold, London 132-141
10. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
11. Hockel M., Schlenger K., Hockel S., et al. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 79 (1998) 365-369
12. Fyles A., Milosevic M., Hedley D., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20 (2002) 680-687
13. Rofstad E. Microenvironment-induced cancer metastasis. Int J Radiat Biol 76 (2000) 589-605
14. Dachs G., and Tozer G. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 36 (2000) 1649-1660
15. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14 (2004) 198-206
16. Grau C., and Overgaard J. Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ. Cancer Chemother Pharmacol 30 (1992) 277-280
17. Chapman J. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother Oncol 20 suppl 1 (1991) 13-19
18. Maxwell P. The HIF pathway in cancer. Semin Cell Dev Biol 16 (2005) 523-530
19. Loncaster J., Harris A., Davidson S., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61 (2001) 6394-6399
20. Overgaard J., Eriksen J., Nordsmark M., et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
21. 2 tension measurements. Cancer Res 51 (1991) 3316-3322
22. International Atomic Energy Agency. Predictive assays and their role in selection of radiation as the therapeutic modality. IAEA-TECDOC-1297 (2002), IAEA, Vienna
23. Barentsz J., Engelbrecht M., Jager G., et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 10 (1999) 295-304
24. Milosevic M., Fyles A., Hedley D., et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61 (2001) 6400-6405
25. NCI, CIP, MR. Workshop on translational research in cancer: recommendations for MR measurement methods at 1·5-Tesla and endpoints for use in phase 1/2a trials of anti-cancer therapeutics affecting tumor vascular function. http://imaging.cancer.gov/reportsandpublications/ReportsandPresentations/MagneticResonance (accessed Dec 11, 2006)
26. Brix G., Semmler W., Port R., et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15 (1991) 621-628
27. Padhani A., and Husband J. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56 (2001) 607-620
28. Evelhoch J. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10 (1999) 254-259
29. Leach M., Brindle K., Evelhoch J., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92 (2005) 1599-1610
30. Tofts P., Berkowitz B., and Schnall M. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33 (1995) 564-568
31. Larsson H., Stubgaard M., Frederiksen J., et al. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 16 (1990) 117-131
32. Tofts P., Brix G., Buckley D., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 (1999) 223-232
33. Weinmann H., Laniado M., and Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16 (1984) 167-172
34. Mayr N., Yuh W., Arnholt J., et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12 (2000) 1027-1033
35. Hayes C., Padhani A., and Leach M. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15 (2002) 154-163
36. Bentzen S. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6 (2005) 112-117
37. Hawighorst H., Weikel W., Knapstein P., et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4 (1998) 2305-2312
38. Postema S., Pattynama P., van Rijswijk C., and Trimbos J. Cervical carcinoma: can dynamic contrast-enhanced MR imaging help predict tumor aggressiveness?. Radiology 210 (1999) 217-220
39. Cooper R., Carrington B., Loncaster J., et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57 (2000) 53-59
40. Yamashita Y., Baba T., Baba Y., et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 216 (2000) 803-809
41. Loncaster J., Carrington B., Sykes J., et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 54 (2002) 759-767
42. Buadu L., Murakami J., Murayama S., et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200 (1996) 639-649
43. Stomper P., Herman S., Klippenstein D., et al. Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer 77 (1996) 1844-1849
44. Stomper P., Winston J., Herman S., et al. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 45 (1997) 39-46
45. Hulka C., Edmister W., Smith B., et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205 (1997) 837-842
46. Esserman L., Hylton N., George T., and Weidner N. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 5 (1999) 13-21
47. Matsubayashi R., Matsuo Y., Edakuni G., et al. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 217 (2000) 841-848
48. George M., Dzik-Jurasz A., Padhani A., et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 88 (2001) 1628-1636
49. Konouchi H., Asaumi J., Yanagi Y., et al. Evaluation of tumor proliferation using dynamic contrast enhanced-MRI of oral cavity and oropharyngeal squamous cell carcinoma. Oral Oncol 39 (2003) 290-295
50. Tynninen O., Aronen H., Ruhala M., et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 34 (1999) 427-434
51. Roberts H., Roberts T., Bollen A., et al. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 8 (2001) 384-391
52. West C., Cooper R., Loncaster J., et al. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res 61 (2001) 2907-2910
53. Weidner N., Semple J., Welch W., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
54. Porschen R., Classen S., Piontek M., and Borchard F. Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation. Cancer Res 54 (1994) 587-591
55. Hawighorst H., Knapstein P., Weikel W., et al. Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 57 (1997) 4777-4786
56. Knopp M., Weiss E., Sinn H., et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10 (1999) 260-266
57. Dvorak H., Brown L., Detmar M., and Dvorak A. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 (1995) 1029-1039
58. Mayr N., Yuh W., Magnotta V., et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 36 (1996) 623-633
59. Mayr N., Yuh W., Zheng J., et al. Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am J Roentgenol 170 (1998) 177-182
60. Hawnaur J., Zhu X., and Hutchinson C. Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancer. Br J Radiol 71 (1998) 1136-1142
61. Gong Q., Brunt J., Romaniuk C., et al. Contrast enhanced dynamic MRI of cervical carcinoma during radiotherapy: early prediction of tumour regression rate. Br J Radiol 72 (1999) 1177-1184
62. Montebello J., Mayr N., Yuh W., et al. Quantitative analysis of heterogenous tumour enhancement pattern and correlation with outcome in cervical cancer. J Clin Oncol 23 suppl 16S (2005) 5095
63. de Vries A., Griebel J., Kremser C., et al. Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. Radiology 217 (2000) 385-391
64. Baba Y., Furusawa M., Murakami R., et al. Role of dynamic MRI in the evaluation of head and neck cancers treated with radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 783-787
65. Tomura N., Omachi K., Sakuma I., et al. Dynamic contrast-enhanced magnetic resonance imaging in radiotherapeutic efficacy in the head and neck tumors. Am J Otolaryngol 26 (2005) 163-167
66. Semiz Oysu A., Ayanoglu E., Kodalli N., et al. Dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrosis from recurrent carcinoma of the head and neck. Clin Imaging 29 (2005) 307-312
67. Hawighorst H., Engenhart R., Knopp M., et al. Intracranial meningeomas: time- and dose-dependent effects of irradiation on tumor microcirculation monitored by dynamic MR imaging. Magn Reson Imaging 15 (1997) 423-432
68. Fuss M., Wenz F., Essig M., et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys 51 (2001) 478-482
69. Tomoi M., Maeda M., Yoshida M., et al. Assessment of radiotherapeutic effect on brain tumors by dynamic susceptibility contrast MR imaging: a preliminary report. Radiat Med 17 (1999) 195-199
70. Essig M., Waschkies M., Wenz F., et al. Assessment of brain metastases with dynamic susceptibility-weighted contrast-enhanced MR imaging: initial results. Radiology 228 (2003) 193-199
71. Weber M., Thilmann C., Lichy M., et al. Assessment of irradiated brain metastases by means of arterial spin-labeling and dynamic susceptibility-weighted contrast-enhanced perfusion MRI: initial results. Invest Radiol 39 (2004) 277-287
72. Dobson M., Carrington B., Collins C., et al. The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging. Clin Radiol 56 (2001) 94-98
73. Ohno Y., Nogami M., Higashino T., et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging 21 (2005) 775-783
74. Barentsz J., Berger-Hartog O., Witjes J., et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207 (1998) 791-797